Akcea lifted by news of FDA approval for Tegsedi

8 October 2018

Shares of US biotech firm Akcea Therapeutics (Nasdaq: AKCA) gained 4.39% to $31.85 by close of trading and a further 2.04% to $32.50 in after-hours on Friday, after the company revealed that the US Food and Drug Administration had approved Tegsedi (inotersen) for the treatment of the polyneuropathy of hereditary transthyretin (hATTR) amyloidosis in adults.

Tegsedi, which also gained approval from the European Medicines agency in July this year, is now the first and only RNA-targeting therapeutic that powerfully reduces the production of TTR protein through a once-weekly subcutaneous injection. Additionally, the drug gained Canadian approval this month.

Akcea acquired rights to Tegsedi in April from Ionis Pharmaceuticals (Nasdaq: IONS), whose share also rose 2.63% to $48.73 on the news.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK